Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from United Therapeutics ( (UTHR) ).
On March 2, 2026, United Therapeutics reported that its pivotal phase 3 ADVANCE OUTCOMES trial of ralinepag in pulmonary arterial hypertension met its primary endpoint, cutting the risk of clinical worsening events by 55% versus placebo and showing statistically significant gains in six-minute walk distance and NT-proBNP. The once-daily oral prostacyclin candidate delivered consistent benefits across heavily pre-treated patient subgroups with a safety profile in line with known prostacyclin effects, reinforcing its potential to reshape the PAH treatment landscape as the company prepares to present full data and pursue U.S. regulatory approval by the second half of 2026.
The most recent analyst rating on (UTHR) stock is a Hold with a $471.00 price target. To see the full list of analyst forecasts on United Therapeutics stock, see the UTHR Stock Forecast page.
Spark’s Take on UTHR Stock
According to Spark, TipRanks’ AI Analyst, UTHR is a Outperform.
The score is driven primarily by exceptional financial performance (high profitability, strong cash generation, and debt-free balance sheet). Earnings-call commentary supports continued growth with meaningful pipeline catalysts, partly offset by binary execution/regulatory risks and emerging competition. Technically, the stock is trending strongly but appears overbought, and valuation is reasonable with no dividend data provided.
To see Spark’s full report on UTHR stock, click here.
More about United Therapeutics
United Therapeutics Corporation is a public benefit biotechnology company focused on transforming the treatment of rare diseases, particularly pulmonary arterial hypertension, and pioneering alternatives to expand the supply of transplantable organs. The company develops innovative therapies and manufactured organ technologies, aiming to create long-term shareholder value while serving patients and operating with sustainable practices.
Average Trading Volume: 398,978
Technical Sentiment Signal: Buy
Current Market Cap: $22.08B
See more insights into UTHR stock on TipRanks’ Stock Analysis page.